Intelligent Clinical Decision Support to Improve Safe Opioid Management of Chronic Noncancer Pain in Primary Care

REFERENCES

1. ↵
   1. Daubresse M.,
   2. Chang HY.,
   3. Yu Y.,
   4. et al.

   Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010. Med Care. 2013 10; 51 10: 870- 878. doi: 10.1097/MLR.0b013e3182a95d86. pmid:24025657

   OpenUrlCrossRefPubMed
2. ↵
   Quality improvement guidelines for the treatment of acute pain and cancer pain. American Pain Society Quality of Care Committee. JAMA. 1995 12 20; 274 23: 1874- 1880. pmid:7500539

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Manchikanti L.,
   2. Abdi S.,
   3. Atluri S.,
   4. et al.

   American Society of Interventional Pain Physicians. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2—guidance. Pain Physician. 2012 7; 15 3 Suppl: S67- S116. pmid:22786449

   OpenUrlPubMedWeb of Science
4. ↵
   Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers—United States 1999-2008. MMWR Morb Mortal Wkly Rep. 2011 11 4; 60 43: 1487- 1492. pmid:22048730

   OpenUrlPubMed
5. ↵
   1. Meyer R.,
   2. Patel AM.,
   3. Rattana SK.,
   4. Quock TP.,
   5. Mody SH.

   Prescription opioid abuse: a literature review of the clinical and economic burden in the United States. Popul Health Manag. 2014 12; 17 6: 372- 387. doi: 10.1089/pop.2013.0098. pmid:25075734

   OpenUrlCrossRefPubMed
6. ↵
   1. Dowell D.,
   2. Haegerich TM.

   Using the CDC guideline and tools for opioid prescribing in patients with chronic pain. Am Fam Physician. 2016 6 15; 93 12: 970- 972. pmid:27304765

   OpenUrlPubMed
7. ↵
   1. Webster LR.,
   2. Webster RM.

   Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005 Nov-Dec; 6 6: 432- 442. pmid:16336480

   OpenUrlCrossRefPubMed
8. ↵
   1. Krebs EE.,
   2. Bair MJ.,
   3. Damush TM.,
   4. Tu W.,
   5. Wu J.,
   6. Kroenke K.

   Comparative responsiveness of pain outcome measures among primary care patients with musculoskeletal pain. Med Care. 2010 11; 48 11: 1007- 1014. doi: 10.1097/MLR.0b013e3181eaf835. pmid:20856144

   OpenUrlCrossRefPubMed
9. ↵
   1. Tan G.,
   2. Jensen MP.,
   3. Thornby JI.,
   4. Shanti BF.

   Validation of the brief pain inventory for chronic nonmalignant pain. J Pain. 2004 3; 5 2: 133- 137. pmid:15042521

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Grattan A.,
    2. Sullivan MD.,
    3. Saunders KW.,
    4. Campbell CI.,
    5. Von Korff MR.

    Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuse. Ann Fam Med. 2012 Jul-Aug; 10 4: 304- 311. doi: 10.1370/afm.1371. pmid:22778118

    OpenUrlAbstract/FREE Full Text
11. 1. Howe CQ.,
    2. Sullivan MD.,
    3. Saunders KW.,
    4. et al.

    Depression and ambivalence toward chronic opioid therapy for chronic noncancer pain. Clin J Pain. 2012 9; 28 7: 561- 566. doi: 10.1097/AJP.0b013e31823ade59. pmid:22699127

    OpenUrlCrossRefPubMed
12. ↵
    1. Merrill JO.,
    2. Von Korff M.,
    3. Banta-Green CJ.,
    4. et al.

    Prescribed opioid difficulties, depression and opioid dose among chronic opioid therapy patients. Gen Hosp Psychiatry. 2012 Nov-Dec; 34 6: 581- 587. doi: 10.1016/j.genhosppsych.2012.06.018. pmid:22959422

    OpenUrlCrossRefPubMed
13. ↵
    1. Kroenke K.,
    2. Spitzer RL.,
    3. Williams JB.,
    4. Löwe B.

    An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009 Nov-Dec; 50 6: 613- 621. doi: 10.1176/appi.psy.50.6.613. pmid:19996233

    OpenUrlCrossRefPubMedWeb of Science
14. 1. Kroenke K.,
    2. Spitzer RL.,
    3. Williams JB.

    The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 9; 16 9: 606- 613. pmid:11556941

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Plummer F.,
    2. Manea L.,
    3. Trepel D.,
    4. McMillan D.

    Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016 Mar-Apr; 39: 24- 31. doi: 10.1016/j.genhosppsych.2015.11.005. pmid:26719105

    OpenUrlCrossRefPubMed
16. 1. Ruiz MA.,
    2. Zamorano E.,
    3. García-Campayo J.,
    4. Pardo A.,
    5. Freire O.,
    6. Rejas J.

    Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care. J Affect Disord. 2011 2; 128 3: 277- 286. doi: 10.1016/j.jad.2010.07.010. pmid:20692043

    OpenUrlCrossRefPubMed
17. ↵
    1. Spitzer RL.,
    2. Kroenke K.,
    3. Williams JB.,
    4. Löwe B.

    A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 5 22; 166 10: 1092- 1097. pmid:16717171

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    1. Fischer F.,
    2. Lange K.,
    3. Klose K.,
    4. Greiner W.,
    5. Kraemer A.

    Barriers and strategies in guideline implementation-a scoping review. Healthcare (Basel). 2016 6 29; 4 3 doi: 10.3390/healthcare4030036.
19. ↵
    1. Sirajuddin AM.,
    2. Osheroff JA.,
    3. Sittig DF.,
    4. Chuo J.,
    5. Velasco F.,
    6. Collins DA.

    Implementation pearls from a new guidebook on improving medication use and outcomes with clinical decision support. Effective CDS is essential for addressing healthcare performance improvement imperatives. J Healthc Inf Manag. 2009 Fall; 23 4: 38- 45.

    OpenUrlPubMed